A phase 1/2 clinical trial of GS010 showed visual acuity improvement in subjects with vision loss due to Leber hereditary optic neuropathy, according to a press release from GenSight Biologics.
A single intravitreal injection of GS010 was administered to the eye more severely affected by the disease in 15 subjects. At the time of treatment, subjects had an onset of vision loss of 6 years, according to the release.
Long-term follow-up, which is ongoing, showed relatively better vision at 2.5 years after injection for subjects who had an onset of (Read more...)
Uncategorized